SLC5A2 and type 2 diabetes mellitus: SGLT2 inhibitors cause significant reductions in HF hospitalisations and mortality in HFrEF patients with or without type 2 diabetes (81–83), and also improve outcomes in HFpEF (8, 9), meaning that for the first time we have a treatment for HFpEF that improves clinical outcomes.